Odonate Therapeutics, Inc. (ODT) |
| 1.12 -0.05 (-4.27%) 04-24 15:47 |
| Open: | 1.16 |
| High: | 1.2 |
| Low: | 1.1107 |
| Volume: | 716,440 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.41 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 40.42 |
| Resistance 1: | 37.06 |
| Pivot price: | 35.97 |
| Support 1: | 31.64 |
| Support 2: | 26.32 |
| 52w High: | 28.41 |
| 52w Low: | 0.85 |
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Financials
| EPS | 0.600 |
| Book Value | 9.180 |
| PEG Ratio | 0.00 |
| Gross Profit | 5.298 |
| Profit Margin (%) | 9.55 |
| Operating Margin (%) | 14.11 |
| Return on Assets (ttm) | 4.0 |
| Return on Equity (ttm) | 7.0 |
Company news
Thu, 28 Sep 2023
Orally Disintegrating Tablet (ODT) Market Analysis, Size, Current Scenario and Future Prospects - openPR.com
Fri, 07 Jan 2022
Odonate Announces Expected Delisting of Its Stock - Business Wire
Tue, 27 Jul 2021
Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 - Business Wire
Mon, 22 Mar 2021
Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel - Business Wire
Thu, 17 Dec 2020
BeyondSpring Appoints Dr. Jeffrey Vacirca to Board - citybuzz -
Wed, 02 Dec 2020
Odonate Therapeutics Stock Price Forecast. Should You Buy ODT? - StockInvest.us
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
